Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01276899 | Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | completed | — | 80 | Jewish General HospitalOTHER | 2 | Jun 2, 2022 | clinicaltrials |
| NCT01904903 | Cardiac Safety Study in Patients With HER2 + Breast Cancer(SAFE-HEaRt) | completed | Phase 2 | 31 | Medstar Health Research InstituteOTHER | 1 | May 10, 2022 |
| clinicaltrials |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03243838 | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer(LANCET) | completed | Phase 2 | 31 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03281824 | Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients | completed | Phase 1 | 27 | Alteogen, Inc.INDUSTRY | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | completed | Phase 3 | 809 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Jan 14, 2022 | clinicaltrials |
| NCT02555657 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | completed | Phase 3 | 622 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 10, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03457779 | Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer | completed | N/A | 16 | Baylor Research InstituteOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01931163 | NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer(NECTAR) | completed | Phase 2 | 24 | Jenny C. Chang, MDOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT03411161 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Institut de Recherches Internationales ServierOTHER | 4 | May 25, 2021 | clinicaltrials |
| NCT03197389 | Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. | completed | Early Phase 1 | 54 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT02413320 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer(NeoSTOP) | completed | Phase 2 | 101 | Priyanka SharmaOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT03577743 | Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 54 | Assiut UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT04756921 | 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response | completed | — | 30 | Biyun Wang, MDOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT03243331 | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | completed | Phase 1 | 18 | Kathy MillerOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT02375958 | PCA062 in pCAD-positive Tumors. | completed | Phase 1 | 47 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03544125 | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01983501 | A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer | completed | Phase 1 | 57 | Seagen Inc.INDUSTRY | 2 | Sep 21, 2020 | clinicaltrials |
| NCT02622074 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | completed | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 10, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT00005970 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | completed | Phase 3 | 3,436 | National Cancer Institute (NCI)NIH | 4 | Aug 14, 2020 | clinicaltrials |
| NCT03140553 | TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer(neoCARH) | completed | Phase 2 | 140 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT02362958 | A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | completed | Phase 2 | 159 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02247037 | Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer | completed | — | 68 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02348320 | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02038010 | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx | completed | Phase 1 | 17 | Northwestern UniversityOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT01216111 | Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) | completed | Phase 3 | 647 | Fudan UniversityOTHER | 0 | May 19, 2020 | clinicaltrials |
| NCT01855828 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | completed | Phase 2 | 50 | Yale UniversityOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT00684983 | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2020 | clinicaltrials |
| NCT00343109 | Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer | completed | Phase 2 | 38 | University of WashingtonOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT01355393 | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT00390455 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | completed | Phase 3 | 295 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2022source: clinicaltrials